SCHEMBL6715700

SCHEMBL6715700

CCc1cccc(C)c1NNC(=O)C(c1ccccc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
POLB P06746 2/20 0.42
PTGS2 P35354 2/20 0.41
RAB9A P51151 2/20 0.39
HTT P42858 4/20 0.38
P2RX7 Q99572 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
HSD17B10 Q99714 2/20 0.37
ALOX12 P18054 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NLRP3 Q96P20 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6717632 0.81 ATM (0.47) ALDH1A1POLBHTTSMN1; SMN2MEN1
SCHEMBL6715480 0.77 ALDH1A1 (0.48) ALDH1A1POLBPTGS2RAB9AHTT
SCHEMBL6825248 0.76 ALDH1A1 (0.47) ALDH1A1POLBPTGS2RAB9AHTT
SCHEMBL6714547 0.76 ALDH1A1 (0.46) ALDH1A1PTGS2
SCHEMBL6717585 0.75 TP53 (0.46) MEN1KMT2ANLRP3
SCHEMBL6716842 0.74 CYP1A2 (0.48) ALDH1A1POLBRAB9AHTTSMN1; SMN2
SCHEMBL6716835 0.74 CYP1A2 (0.48) ALDH1A1POLBRAB9AHTTSMN1; SMN2
SCHEMBL6719501 0.74 MAPT (0.46) ALDH1A1POLBPTGS2RAB9AHTT
SCHEMBL6715970 0.73 SLC1A3 (0.41) ALDH1A1SMN1; SMN2ALOX12MEN1KMT2A
SCHEMBL6718599 0.73 CASP2 (0.38) ALDH1A1RAB9AHTTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885POLB 4182/4885PTGS2 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.